Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

After a successful appeal, reimbursement authority NICE has said the companies' files will now be sent back to the appraisal ...

The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for cognition or function in patients with early Alzheimer’s.

Evoke and Evoke+ -- the randomized, double-blind, placebo-controlled phase 3 trials conducted across 566 sites in 40 ...

The NHS will reconsider approving two Alzheimer’s “wonder drugs” after a successful appeal. The National Institute of Health and Care Excellence , which assesses the cost-ef ...

After decades of slow progress in understanding and developing effective treatments for Alzheimer’s disease, scientists are ...

The NHS spending watchdog must look again at its decision after drug manufacturers successfully appealed against Nice's ruling that the treatments were not cost-effective ...

The U.K.’s national health spending watchdog will reevaluate its decision to exclude the use of two Alzheimer’s drugs ...

A key Alzheimer’s drug has finally revealed its secret. Researchers discovered that lecanemab works by activating the brain’s immune cells—but only through a specific part of the antibody called the ...

In the brain, Alzheimer’s is characterized by two proteins, amyloid beta and tau, that become dysfunctional, forming plaques ...

Scientists reverse Alzheimer's memory loss in mice by using NAD+ to restore brain energy, defying decades of research.

Alzheimer's disease affects millions of people worldwide, yet the illness is hardest to catch at the very beginning, when new ...